What happened. Shares of Vaxart (Nasdaq: VXRT) rose on Monday after the biotech said the U.S. Food and Drug Administration...
vxrt stock
Out of 4 analysts, 3 (75%) are recommending VXRT as a Strong Buy, 0 (0%) are recommending VXRT as a...
The biotech’s stock has been sliding hard over the past month and half for two related reasons: Vaxart’s oral COVID-19...
NEWS for Vaxart, Inc. … Munafa value: 40 as on 08 Fri Apr 2022. Downside target 4.5 Upside target 4.79...
